LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

20.78 -0.95

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.6

Максимум

21.32

Ключови измерители
By Trading Economics
Приходи	-29M -11M
Продажби	-24M 105M
EPS	-0.09
Марж на печалбата	-10.717
Служители	354
EBITDA	-31M -8.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+64.83% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-433M 2.5B
Предишно отваряне	21.73
Предишно затваряне	20.78

Настроения в новините

By Acuity

50%

155 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.05.2026 г., 16:33 ч. UTC

Печалби

Значими двигатели на пазара

Webull Shares Slide on 1Q Loss, Soaring Costs

22.05.2026 г., 21:10 ч. UTC

Печалби

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 19:47 ч. UTC

Печалби

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22.05.2026 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22.05.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22.05.2026 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22.05.2026 г., 18:09 ч. UTC

Пазарно говорене

Centralized Crypto Lending Slows in 1Q -- Market Talk

22.05.2026 г., 17:58 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22.05.2026 г., 17:03 ч. UTC

Пазарно говорене

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22.05.2026 г., 16:54 ч. UTC

Пазарно говорене

Crypto Spot Volumes Fall 14% in April -- Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 16:16 ч. UTC

Пазарно говорене

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

22.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22.05.2026 г., 15:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.05.2026 г., 15:42 ч. UTC

Пазарно говорене

Oil Continues as Leading Indicator for All Markets -- Market Talk

22.05.2026 г., 15:35 ч. UTC

Пазарно говорене

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

64.83% нагоре

12-месечна прогноза

Среден 34.63 USD 64.83%

Висок 36 USD

Нисък 33 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

155 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.